Abstract
Nitric oxide (NO) is a potent cell signaling and effector molecule that participates in numerous physiological and pathophysiological events in a variety of cell types and tissues. NO derived from all major isoforms of NO synthase can S-nitrosylate cysteine thiols in target proteins, potentially altering their functional activities in a redox-dependent, cGMP-independent manner. Formation of protein S-nitrosocysteine adducts appears to occur through multiple pathways. Emerging evidence suggests that S-nitrosylation is a specific, reversible and regulated covalent post-translational modifi-cation that modulates diverse biological and physiological functions. In addition to altering protein activity, localization and stability, S-nitrosylation participates in the control of cellular metabolism, apoptosis, protein – protein interactions, transcription factor function, ion channel activity and cellular redox balance. Increasingly sophisticated proteomic ap-proaches used in various cell types and tissues have identified S-nitrosylation of proteins of virtually all major classes, in-cluding cytoskeletal proteins, chaperones, proteins of the translational and transcriptional machinery, vesicular transport and signaling. S-nitrosylation has also been shown to regulate the NO synthase isoforms themselves, reversibly inhibiting endothelial NO synthase activity and feedback inhibiting PARP-1, a transactivator of inducible NO synthase. Imbalances in NO metabolism and dysregulated S-nitrosylation have been implicated in a growing list of human diseases, such as neurodegenerative disorders, endotoxemic shock and insulin resistance. Here we review the key discoveries and directions in this field, including the role of S-nitrosylation as a potential therapeutic target in specific human diseases.
Keywords: NO synthase, S-Nitrosoproteome, NADPH, Diabetes Mellitus, Neurodegenerative Diseases, Pulmonary Diseases
Current Genomics
Title: S-Nitrosylation: Targets, Controls and Outcomes
Volume: 7 Issue: 5
Author(s): Bruce C. Kone
Affiliation:
Keywords: NO synthase, S-Nitrosoproteome, NADPH, Diabetes Mellitus, Neurodegenerative Diseases, Pulmonary Diseases
Abstract: Nitric oxide (NO) is a potent cell signaling and effector molecule that participates in numerous physiological and pathophysiological events in a variety of cell types and tissues. NO derived from all major isoforms of NO synthase can S-nitrosylate cysteine thiols in target proteins, potentially altering their functional activities in a redox-dependent, cGMP-independent manner. Formation of protein S-nitrosocysteine adducts appears to occur through multiple pathways. Emerging evidence suggests that S-nitrosylation is a specific, reversible and regulated covalent post-translational modifi-cation that modulates diverse biological and physiological functions. In addition to altering protein activity, localization and stability, S-nitrosylation participates in the control of cellular metabolism, apoptosis, protein – protein interactions, transcription factor function, ion channel activity and cellular redox balance. Increasingly sophisticated proteomic ap-proaches used in various cell types and tissues have identified S-nitrosylation of proteins of virtually all major classes, in-cluding cytoskeletal proteins, chaperones, proteins of the translational and transcriptional machinery, vesicular transport and signaling. S-nitrosylation has also been shown to regulate the NO synthase isoforms themselves, reversibly inhibiting endothelial NO synthase activity and feedback inhibiting PARP-1, a transactivator of inducible NO synthase. Imbalances in NO metabolism and dysregulated S-nitrosylation have been implicated in a growing list of human diseases, such as neurodegenerative disorders, endotoxemic shock and insulin resistance. Here we review the key discoveries and directions in this field, including the role of S-nitrosylation as a potential therapeutic target in specific human diseases.
Export Options
About this article
Cite this article as:
C. Kone Bruce, S-Nitrosylation: Targets, Controls and Outcomes, Current Genomics 2006; 7 (5) . https://dx.doi.org/10.2174/138920206778604340
DOI https://dx.doi.org/10.2174/138920206778604340 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of the NMDA-Receptor Antagonist Dextromethorphan in Infant Rat Pneumococcal Meningitis
Current Drug Metabolism The Adipose Tissue as a Source of Vasoactive Factors
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Adipose Tissue and Bone Marrow as Sources for Cell-based Therapeutic Angiogenesis in Ischemic Tissues: Biological Foundation and Clinical Prospects for Age-related Vascular Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Sonic Hedgehog Pathway as a Target for Therapy in Angiogenesis-Related Diseases
Current Signal Transduction Therapy High Fat Meal Increase of IL-17 is Prevented by Ingestion of Fruit Juice Drink in Healthy Overweight Subjects
Current Pharmaceutical Design Early Growth Response-1 (EGR-1) – A Key player in Myocardial Cell Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Modulation of Cardiac Metabolism During Myocardial Ischemia
Current Pharmaceutical Design Low Level Laser Therapy [LLLT] in Inflammatory and Rheumatic Diseases:A Review of Therapeutic Mechanisms
Current Rheumatology Reviews Antioxidant Therapy and Drugs Interfering with Lipid Metabolism: Could They Be Effective in NAFLD Patients?
Current Pharmaceutical Design Experimental Rodent Models of Vascular Dementia: A Systematic Review
CNS & Neurological Disorders - Drug Targets Adrenergic and V1-ergic Agonists/Antagonists Affecting Recovery from Brain Trauma in the Lund Project Act on Astrocytes
Current Signal Transduction Therapy Receptor for Advanced Glycation Endproducts (RAGE): A Formidable Force in the Pathogenesis of the Cardiovascular Complications of Diabetes & Aging
Current Molecular Medicine Enkephalin-Fentanyl Multifunctional Opioids as Potential Neuroprotectants for Ischemic Stroke Treatment
Current Pharmaceutical Design The Role of the Thrombospondins in Healing Myocardial Infarcts
Cardiovascular & Hematological Agents in Medicinal Chemistry Natural Therapies of the Inflammatory Bowel Disease: The Case of Rutin and its Aglycone, Quercetin
Mini-Reviews in Medicinal Chemistry Recent Advances Using Phosphodiesterase 4 (PDE4) Inhibitors to Treat Inflammatory Disorders: Animal and Clinical Studies
Current Drug Therapy Neuropeptide Y Induces Cardiomyocyte Hypertrophy <i>via</i> Attenuating miR-29a-3p in Neonatal Rat Cardiomyocytes
Protein & Peptide Letters The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design Polyphenols and Stem Cells for Neuroregeneration in Parkinson’s Disease and Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design The Rise and Fall of NMDA Antagonists for Ischemic Stroke
Current Molecular Medicine